TNGX News and Press, Tango Therapeutics Inc. From 08/09/23

2023-08-09 10:08:11 ET Gainers: Tango Therapeutics ( TNGX ) +137% . Decibel Therapeutics ( DBTX ) +72% . Mirati Therapeutics ( MRTX ) +26% . Azenta ( AZTA ) +25% . Clover Health Investments ( CLOV ) +18 % . Losers: ...

2023-08-07 07:19:02 ET Tango Therapeutics press release ( NASDAQ: TNGX ): Q2 GAAP EPS of -$0.23 beats by $0.08 . Revenue of $14.6M (+152.6% Y/Y) beats by $7.65M . For further details see: Tango Therapeutics GAAP EPS of -$0.23 beats by $0.08, revenue of $1...

– First patient dosed in phase 1/2 trial of TNG462, a next-generation PRMT5 inhibitor for the treatment of MTAP-deleted tumors – – Dose escalation ongoing in phase 1/2 trial of TNG908, a novel brain-penetrant PRMT5 inhibitor for the treatment of MTAP-deleted tumors ...

2023-07-27 08:38:02 ET Mersana Therapeutics ( MRSN ) -74% announces topline data from UPLIFT clinical trial in patients with platinum-resistant Ovarian Cancer and strategic reprioritization. Biohaven ( BHVN ) -27% . Yellow Corporation ( YELL ) -26% . ...

2023-07-26 19:29:51 ET Summary In my previous article, I hoped that Tango publishing POC data would help the stock. They published partial data, and it was not convincing. The stock remains stagnant. I was hoping for some spike on early data update from TNG908, a...

BOSTON, July 24, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial evaluat...

BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial of TNG462 in patients ...

2023-05-09 08:54:19 ET Tango Therapeutics press release ( NASDAQ: TNGX ): Q1 GAAP EPS of -$0.32 beats by $0.03 . Revenue of $5.77M (+0.2% Y/Y) misses by $1M . For further details see: Tango Therapeutics GAAP EPS of -$0.32 beats by $0.03, revenue of $5.77M...

– Dose escalation update from ongoing TNG908 clinical trial confirms proof-of-mechanism for MTA-cooperative tumor-selective PRMT5 inhibition in MTAP-deleted cancers – – FDA clears IND application for TNG260, a first-in-class CoREST complex inhibitor for the treatmen...

2023-04-23 23:47:25 ET The following slide deck was published by Tango Therapeutics, Inc. in conjunction with this event. For further details see: Tango Therapeutics (TNGX) Investor Presentations - Slideshow